admin
Of all the stories swirling around Washington this year, few are as telling as Forbes’ portrait of Kim Rivers, the Florida CEO who has become the cannabis industry’s closest confidante inside the Trump orbit. Rivers didn’t get that label by accident: the reporting makes clear she and Trulieve were central players in pushing the administration toward an executive order to move marijuana out of Schedule I.
President Trump signed that executive order on December 18, 2025, directing federal agencies to begin the formal process of reclassifying marijuana as a less-dangerous Schedule III substance — a move the administration framed as opening the door to more medical research. Conservatives who prize rule of law should note the difference between an order that starts a bureaucratic process and one that changes the statute; the president used his influence, rightly or wrongly, to nudge federal policy.
Trulieve is no mom-and-pop outfit; the company generated roughly $1.2 billion in sales last year and now aims to scale nationwide, chasing a “Starbucks of weed” vision that oligarchs and shareholders salivate over. That level of corporate heft explains why Rivers has access — big money buys big doors in D.C., and the economic clout of companies like Trulieve reshapes policy conversations fast.
Local reporting from Tallahassee and other outlets lays out how Rivers and Trulieve cultivated influence through donations, fundraising and private meetings, even hosting high-dollar events tied to the president’s network. For citizens who distrust pay-to-play politics, this should sound alarm bells: when policy can be steered by the checkbook, the public interest gets short shrift.
There are real policy questions at stake — tax rules like 280E, bank access, and federal-state conflicts — and lawmakers are already squabbling over whether rescheduling will simply hand big cannabis firms an outsized tax break while small operators and communities that suffered under prohibition get left behind. Conservatives who want free markets must demand a level playing field, not a state-enabled oligopoly that benefits the politically connected.
Rivers and Trulieve’s explicit goal to be the national retail face of cannabis should prompt sober debate about commercialization and cultural change. It’s one thing to support medical research and property rights; it’s another to cheer on a corporate consolidation that packages a formerly illicit drug into a Starbucks-style consumer brand.
President Trump deserves credit for challenging federal overreach on medical research, but patriotic conservatives should insist on transparency, accountability and protections against regulatory capture as the rescheduling process moves forward. If America’s laws are to change, let voters and their representatives — not well-funded executives and private fundraisers — drive the debate and the rules that follow.
